Lantern receives FDA clearance for paediatric STAR-001 CNS trial

​Starlight Therapeutics subsidiary Lantern Pharma has secured FDA clearance for its IND application to initiate a Phase I paediatric CNS cancer trial of STAR-001.

The post Lantern receives FDA clearance for paediatric STAR-001 CNS trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Viome PRO introduces blood test for pancreatic cancer
Alpheus begins multi-centre study for butterfly GBM
Biohaven partners with Ono in $100m IgG degrader deal
The pitfalls in hospitals’ ability to auction clinical labour
BD reports nine-month AGILITY trial data for Revello stent

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us